On September 3, 2019 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported it will be featured as a presenting company at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 in New York, NY (Press release, Eleven Biotherapeutics, SEP 3, 2019, View Source [SID1234539191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference
Date: September 10, 2019
Time: 3:25-3:50 PM EDT
Location: Holmes I (4th Floor) room, Lotte New York Palace Hotel, New York, NY

A live webcast of the Company’s presentation will be accessible from the Investors & Media section of Sesen Bio’s website, www.sesenbio.com. An archived replay of the webcast will be available on the Company’s website for 90 days after the conference.